3 Quotes by Graham Parry

We believe that the FDA's immediate concern level with the products is low and see black box as unlikely. A medication guide is more likely because of the strong panel vote in its favor.

Given increasing market hopes of a full approval, we believe that this could disappoint investors.

Although we continue to see attractive long-term growth potential in the shares, we feel that this is now more adequately valued at the current price.